Drug Information

Drug General Information
Drug ID
D0I0EO
Former ID
DNCL002870
Drug Name
ISIS-GCGRrx
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 2 [524338]
Company
Isis Pharmaceuticals
Target and Pathway
Target(s) Glucagon receptor Target Info Modulator [1572591]
KEGG Pathway Neuroactive ligand-receptor interaction
Glucagon signaling pathway
Reactome Glucagon signaling in metabolic regulation
G alpha (q) signalling events
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 524338ClinicalTrials.gov (NCT01885260) Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.